Lenvatinib is the targeted therapy for thyroid cancer. It may be given to treat advanced thyroid cancer when the radioactive iodine treatment does not stop the disorder. It works by inhibiting the activity of proteins known as receptor tyrosine kinases that are involved in cancer growth.